• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biote Corp. (Amendment)

    2/13/24 4:38:50 PM ET
    $BTMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTMD alert in real time by email
    SC 13G/A 1 sc13ga108706btmd_02142024.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    biote Corp.

     (Name of Issuer)

    Class A common stock, par value $0.0001 per share

     (Title of Class of Securities)

    090683103

     (CUSIP Number)

    December 31, 2023

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 090683103

     

      1   NAME OF REPORTING PERSON  
             
            BANDERA PARTNERS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            DELAWARE  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         1,832,732  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              1,832,732  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,832,732  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.4%  
      12   TYPE OF REPORTING PERSON  
             
            IA, OO  

      

    2

    CUSIP No. 090683103

      1   NAME OF REPORTING PERSON  
             
            GREGORY BYLINSKY  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,832,732  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,832,732  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,832,732  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.4%  
      12   TYPE OF REPORTING PERSON  
             
            HC, IN  

      

    3

    CUSIP No. 090683103

     

      1   NAME OF REPORTING PERSON  
             
            JEFFERSON GRAMM  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,832,732  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              1,832,732  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,832,732  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.4%  
      12   TYPE OF REPORTING PERSON  
             
            HC, IN  

      

    4

    CUSIP No. 090683103

     

    Although the Reporting Persons (as defined below) qualified to file the initial Statement on Schedule 13G pursuant to Rule 13d-1(b) under the Securities Exchange Act of 1934, as amended, they elected to voluntarily file the initial Statement on Schedule 13G earlier than was required pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended.

     

    Item 1(a).Name of Issuer:

     

    biote Corp., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    1875 W. Walnut Hill Ln #100

    Irving, Texas 75038

     

    Item 2(a).Name of Person Filing:

    This statement is filed by Bandera Partners LLC, a Delaware limited liability company (“Bandera Partners”), Gregory Bylinsky and Jefferson Gramm. Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Bandera Partners and Messrs. Bylinsky and Gramm are filing this Statement with respect to the Shares (as defined below) directly held by Bandera Master Fund L.P., a Cayman Islands exempted limited partnership (“Bandera Master Fund”).

     

    Bandera Partners is the investment manager of Bandera Master Fund and may be deemed to have beneficial ownership over the Shares held by Bandera Master Fund by virtue of the sole and exclusive authority granted to Bandera Partners by Bandera Master Fund to vote and dispose of such Shares. Messrs. Bylinsky and Gramm are Managing Members of Bandera Partners and may be deemed to beneficially own the Shares held by Bandera Master Fund.

     

    The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares that it or he does not directly own. Without limiting the foregoing sentence, Bandera Master Fund specifically disclaims beneficial ownership of the Shares held by it by virtue of its inability to vote or dispose of such Shares.

    Item 2(b).Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is 50 Broad Street, Suite 1820, New York, New York 10004.

    Item 2(c).Citizenship:

    Bandera Partners is organized under the laws of the State of Delaware. Each of Messrs. Bylinsky and Gramm is a citizen of the United States of America.

    Item 2(d).Title of Class of Securities:

    Class A common stock, par value $0.0001 per share (the “Shares”).

    5

    CUSIP No. 090683103

    Item 2(e).CUSIP Number:

    090683103

    Item 3.If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
        /X/ Not Applicable
      (a) /  / Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
      (b) /  / Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) /  / Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) /  / Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) /  / Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).
      (f) /  / Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F).
      (g) /  / Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G).
      (h) /  / Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
      (i) /  / Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
      (j) /  / Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
      (k) /  / Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

     

    Item 4.Ownership.

    All ownership information reported in this Item 4 is as of the close of business on December 31, 2023.

    Bandera Partners LLC

    (a)Amount beneficially owned:

    1,832,732 Shares

    6

    CUSIP No. 090683103

    (b)Percent of class:

    5.4% (based on 33,940,353 Shares outstanding as of November 9, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2023)

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    1,832,732 Shares

    (ii)Shared power to vote or to direct the vote

    0 Shares

    (iii)Sole power to dispose or to direct the disposition of

    1,832,732 Shares

    (iv)Shared power to dispose or to direct the disposition of

    0 Shares

    Gregory Bylinsky

    (a)Amount beneficially owned:

    1,832,732 Shares

    (b)Percent of class:

    5.4% (based on 33,940,353 Shares outstanding as of November 9, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2023)

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    0 Shares

    (ii)Shared power to vote or to direct the vote

    1,832,732 Shares

    (iii)Sole power to dispose or to direct the disposition of

    0 Shares

    (iv)Shared power to dispose or to direct the disposition of

    1,832,732 Shares

    7

    CUSIP No. 090683103

    Jefferson Gramm

    (a)Amount beneficially owned:

    1,832,732 Shares

    (b)Percent of class:

    5.4% (based on 33,940,353 Shares outstanding as of November 9, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 11, 2023)

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    0 Shares

    (ii)Shared power to vote or to direct the vote

    1,832,732 Shares

    (iii)Sole power to dispose or to direct the disposition of

    0 Shares

    (iv)Shared power to dispose or to direct the disposition of

    1,832,732 Shares

    Item 5.Ownership of Five Percent or Less of a Class.

    Not applicable.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    The right to receive dividends from, or the proceeds from the sale of, the Shares reported herein is held by Bandera Master Fund, a private investment fund for which Bandera Partners serves as investment manager. Bandera Partners and Messrs. Bylinsky and Gramm disclaim beneficial ownership of the Shares reported in this statement pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    8

    CUSIP No. 090683103

    Item 8.Identification and Classification of Members of the Group.

    See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on June 13, 2023.

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    9

    CUSIP No. 090683103

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2024

      BANDERA PARTNERS LLC
       
      By:

    /s/ Gregory Bylinsky

        Name: Gregory Bylinsky
        Title: Managing Member

     

     

     

    /s/ Gregory Bylinsky

      Gregory Bylinsky

     

     

     

    /s/ Jefferson Gramm

      Jefferson Gramm

     

    10

     

    Get the next $BTMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTMD

    DatePrice TargetRatingAnalyst
    12/16/2024Buy
    Craig Hallum
    2/20/2024$9.00Buy
    B. Riley Securities
    2/1/2024Buy
    Jefferies
    More analyst ratings

    $BTMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Biote to Purchase Asteria Health

      Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt

      1/17/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Names Robert Peterson as Chief Financial Officer

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t

      1/11/24 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Announces Purchase of Shares by Directors and CEO

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company") a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that several members of its Board of Directors, along with CEO Bret Christensen, have made open market purchases of Biote's common stock, acquiring an aggregate of approximately 260,000 shares. Marc Beer, Biote Executive Chairman, said, "These share purchases underscore the collective confidence of Biote's Board members and CEO Bret Christensen in the Company's business strategy and long-term outlook. The board is very confident in Bret's ability to make decisive and material changes a

      3/18/25 5:30:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Financials

    Live finance-specific insights

    See more
    • Biote Reports First Quarter 2025 Financial Results

      Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights Revenue of $49.0 million Gross profit margin of 74.3% Net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37, compared to net loss of $(5.7) million and diluted loss per share attributable to biote Corp. stockholders of $(0.12) in the prior year period Adjusted EBITDA1 of $13.8 million and Adjusted EBITDA margin1 of 28.1% Biote (NASDAQ:BTMD), a leading solutions provi

      5/7/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Schedules First Quarter 2025 Financial Results Release and Conference Call

      biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial results on Wednesday, May 7, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be

      4/23/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Reports Fourth Quarter and Full Year 2024 Financial Results

      Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.8 million Procedure revenue of $36.6 million Gross profit margin of 71.8% Net income of $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to

      3/12/25 4:05:00 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Biote Corp.

      10-Q - biote Corp. (0001819253) (Filer)

      5/9/25 4:21:16 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - biote Corp. (0001819253) (Filer)

      5/7/25 4:06:53 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFR14A filed by Biote Corp.

      DEFR14A - biote Corp. (0001819253) (Filer)

      5/5/25 4:51:15 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biote Corp.

      SC 13G/A - biote Corp. (0001819253) (Subject)

      11/12/24 4:15:18 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 5:17:02 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Biote Corp. (Amendment)

      SC 13G/A - biote Corp. (0001819253) (Subject)

      2/14/24 2:11:05 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on biote Corp.

      Craig Hallum initiated coverage of biote Corp. with a rating of Buy

      12/16/24 8:50:55 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • B. Riley Securities initiated coverage on biote Corp. with a new price target

      B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00

      2/20/24 6:47:29 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Jefferies initiated coverage on biote Corp.

      Jefferies initiated coverage of biote Corp. with a rating of Buy

      2/1/24 6:18:15 AM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $BTMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Guines Llc bought $1,461,373 worth of shares (447,714 units at $3.26) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/8/25 7:16:54 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $6,371 worth of shares (1,933 units at $3.30) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      5/2/25 5:12:33 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Guines Llc bought $28,782 worth of shares (8,801 units at $3.27) (SEC Form 4)

      4 - biote Corp. (0001819253) (Issuer)

      4/23/25 4:58:23 PM ET
      $BTMD
      Medicinal Chemicals and Botanical Products
      Health Care